Fentanyl
- Generic Name
- Fentanyl
- Brand Names
- Abstral, Actiq, Duragesic, Effentora, Fentora, Instanyl, Lazanda, Sublimaze, Subsys, PecFent
- Drug Type
- Small Molecule
- Chemical Formula
- C22H28N2O
- CAS Number
- 437-38-7
- Unique Ingredient Identifier
- UF599785JZ
- Background
Fentanyl, a potent opioid agonist, was developed in the 1950s to fill a need for strong and rapid analgesia. Because of these characteristics, fentanyl is commonly used to treat chronic cancer pain or in anesthesia. Fentanyl is related to other opioids like morphine and oxycodone.
Fentanyl's high potency has also made it a common adulterant in illicit drugs, especially heroin. In 2017, 47600 overdose deaths in the United States involved some opioid (over 2/3 of all overdose deaths). Opioid overdoses kill an average of 11 Canadians daily.
Fentanyl was FDA approved in 1968.
- Indication
Fentanyl intravenous or intramuscular injections are indicated for short term analgesia during induction, maintenance, and recovery from general or regional anesthesia. These injections are also used with a neuroleptic for premedication, induction, and as an adjunct to maintenance of anesthesia. Finally, fentanyl intravenous or intramuscular injections are used with oxygen for anesthesia in high risk patients.
Fentanyl sublingual tablets, transmucosal lozenges, buccal tablets, sublingual sprays, transdermal systems, and nasal sprays are indicated for the management of breakthrough pain in opioid tolerant cancer patients who require around the clock pain management.
- Associated Conditions
- Cancer Related Pain (Breakthrough Pain), Severe, Chronic Pain
- Associated Therapies
- Anesthetic premedication therapy, Anesthetics Agent, General Anesthesia, Induction of anesthesia therapy, Maintenance of anesthesia therapy, Regional Anesthesia therapy
Duragesic® (Fentanyl Transdermal System) Functionality Trial in Chronic Low Back Pain
- Conditions
- Low Back Pain
- First Posted Date
- 2005-10-12
- Last Posted Date
- 2013-11-20
- Lead Sponsor
- PriCara, Unit of Ortho-McNeil, Inc.
- Target Recruit Count
- 358
- Registration Number
- NCT00237341
Phase III Clinical Trial of Fentanyl Transdermal Matrix Patch, in the Management of Chronic Intractable Pain- Assessment of Effectiveness, Safety and Pharmacokinetics
- Conditions
- Pain, Intractable
- First Posted Date
- 2005-09-22
- Last Posted Date
- 2011-02-01
- Lead Sponsor
- Janssen Pharmaceutical K.K.
- Target Recruit Count
- 139
- Registration Number
- NCT00216684
Phase II Clinical Trial of Fentanyl Transdermal Matrix Patch, in the Management of Cancer Pain- Assessment of Effectiveness, Safety and Pharmacokinetics -
- Conditions
- Pain, Intractable
- First Posted Date
- 2005-09-22
- Last Posted Date
- 2011-01-24
- Lead Sponsor
- Janssen Pharmaceutical K.K.
- Target Recruit Count
- 87
- Registration Number
- NCT00216658
Study of Fentanyl-Propofol-EMLA of L.M.X4 Technique for Bone Marrow Aspiration
- Conditions
- PainBone Marrow Disease
- Interventions
- First Posted Date
- 2005-09-16
- Last Posted Date
- 2017-04-04
- Lead Sponsor
- St. Jude Children's Research Hospital
- Target Recruit Count
- 168
- Registration Number
- NCT00187135
- Locations
- 🇺🇸
St. Jude Children's Research Hospital, Memphis, Tennessee, United States
Pharmaco-Economic Study Of Ultiva In Intensive Care Unit(ICU)Subjects
- Conditions
- Sedation
- First Posted Date
- 2005-09-12
- Last Posted Date
- 2008-10-16
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 224
- Registration Number
- NCT00158873
- Locations
- 🇳🇱
GSK Investigational Site, Zwolle, Netherlands
Sensory Examination and Pharmacological Modulation of Oral Hyperexcitability in Patients With Atypical Odontalgia and Matched Healthy Controls
- Conditions
- Odontalgia
- First Posted Date
- 2005-06-21
- Last Posted Date
- 2006-06-20
- Lead Sponsor
- University of Aarhus
- Target Recruit Count
- 20
- Registration Number
- NCT00115102
- Locations
- 🇩🇰
Danish Pain Research Center, Aarhus, Denmark
Characterization of Pain Processing Mechanisms in Irritable Bowel Syndrome
- Conditions
- Irritable Bowel Syndrome
- First Posted Date
- 2005-04-18
- Last Posted Date
- 2009-01-21
- Lead Sponsor
- US Department of Veterans Affairs
- Registration Number
- NCT00108446
- Locations
- 🇺🇸
Malcom Randall VAMC, Gainesville, Florida, United States
Herb-Opioid Interactions
- Conditions
- Pain
- First Posted Date
- 2001-11-16
- Last Posted Date
- 2007-02-08
- Lead Sponsor
- National Center for Complementary and Integrative Health (NCCIH)
- Target Recruit Count
- 54
- Registration Number
- NCT00027014
- Locations
- 🇺🇸
Fred Hutchinson Cancer Research Center, Seattle, Washington, United States
Randomized Study of Propofol Versus Fentanyl and Midazolam in Pediatric Patients Requiring Mechanical Ventilation and Sedation Therapy
- Conditions
- Respiration Disorders
- First Posted Date
- 1999-10-19
- Last Posted Date
- 2015-03-25
- Lead Sponsor
- FDA Office of Orphan Products Development
- Target Recruit Count
- 120
- Registration Number
- NCT00004424
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.